Editorial Board


Camillo Porta
IRCCS San Matteo, University Hospital Foundation, Piazzale C. Golgi 19, Pavia, Italy
Tel.: +39-0382-501355; Fax: +39-0382-526223; e-mail: c.porta@smatteo.pv.it

Advisory Editorial Board

Joaquim Bellmunt, Solid Tumor Oncology (Genitourinary and Gastrointestinal), Medical Oncology Service, Hospital Del Mar, Barcelona, Spain
Daniel D. Billadeadu, Department of Immunology and Division of Oncology Research, Schulze Center for Novel Therapeutics, College of Medicine, Mayo Clinic, Rochester, MN, USA
Marco Bregni, Medical Oncology Unit, Ospedale San Giuseppe; Department of Hematology, Istituto Scientifico San Raffaele, Milano, Italy
Aman U. Buzdar, University of Texas MD Anderson Cancer Center, Houston, TX, USA
Ronald M. Bukowski, Experimental Therapeutics, Hematology and Medical Oncology, Cleveland Clinic Taussig Cancer Center, Cleveland, OH, USA
Michele Carbone, Cancer Research Center of Hawaii, University of Hawaii, Honolulu, HI, USA
Zhi-yi Chen, Department of Medical Ultrasound, The Third Affiliated Hospital of Guangzhou Medical University, The Medical Center for Critical Pregnant Women in Guangzhou, China
Pierfranco Conte, Department of Oncology and Haematology, University of Modena and Reggio Emilia, Modena, Italy
Ramon Andrade de Mello, Department of Medical Oncology, Portuguese Oncology Institute, Porto, Portugal
Prasenjit Dey, Department of Genomic Medicine, MD Anderson Cancer Center, Houston, TX, USA
Tim Eisen, Department of Medicine, Royal Marsden Hospital, Sutton, Surrey, UK
Bernard J. Escudier, Institut Gustave Roussy, Villejuif, France
Dean A. Fennell, Centre for Cancer Research and Cell Biology, Queens University Belfast, Belfast, Northern Ireland
Giovanni Gaudino, Italian Mesothelioma Group, Gruppo Italiano Mesotelioma - GIMe, Pavia, Italy; Department of Chemical, Food, Pharmaceutical and Pharmacological Sciences and Drug and Food Biotechnology Center, University of Piemonte Orientale ‘A. Avogadro’, Novara, Italy
Robert G. Gish, California Pacific Medical Center, San Francisco, CA, USA
John M. Kirkwood, Melanoma and Skin Cancer Program, Department of Medicine, Dermatology, and Translational Science, University of Pittsburgh School of Medicine, University of Pittsburgh Cancer Institute, Pittsburgh, PA, USA
Bhavani Krishnan, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC, USA
Deepa Kushwaha, Rare Genomics Institute/RareShare, Hanover, MD, USA
Roberto Labianca, Department of Oncology, Ospedali Riuniti, Bergamo, Italy
Wenyu Liu, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA
Luciano Mutti, Ospedale SS. Pietro e Paolo di Borgosesia, Borgosesia (VC), Italy; Italian Mesothelioma Group, Gruppo Italiano Mesotelioma - GIMe, Pavia, Italy
Giovanni Rosti, Department of Oncology and Hematology, Istituto Oncologico Romagnolo Ospedale Civile, Ravenna, Italy
Ugo Rovigatti, Department of Oncology, University of Pisa Medical School, Italy
Youcef M. Rustum, Department of Pharmacology and Therapeutics, Grace Cancer Drug Center, Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, New York, NY, USA
Giorgio V. Scagliotti, Department of Clinical & Biological Sciences, Thoracic Oncology Unit, San Luigi Hospital, University of Turin, Regione Gonzole, Orbassano (TO), Italy; Department of Clinical and Biological Sciences Thoracic Oncology UNIT, San Luigi Hospital, University of Turin, Orbassano (TO), Italy
Cristiana Sessa, Oncology Institute of Southern Switzerland, San Giovanni Hospital, Bellinzona, Switzerland
Salvatore Siena, Divisione Oncologia Medica Falck, Ospedale Niguarda Ca’ Granda, Milan, Italy
Daniel H. Sterman, University of Pennsylvania Medical Center, Philadelphia, PA, USA
Cora N. Sternberg, San Camillo Forlanini Hospital, Rome, Italy
Cezary Szczylik, Military Institute of Medicine and Health Services, Warsaw, Poland
Lixia Zhao, Loyola University Medical Center, Maywood, IL, USA